Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (131-140 of 437) with videos related to

Pageof 44
Sort By:
Clinical Lung Cancer|May 11, 2023
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122)Nikolaj Frost, Annalen Bleckmann, Frank Griesinger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2011
Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390)Janessa Laskin, Lucio Crinò, Enriqueta Felip, et al.
Lung Cancer (Amsterdam, Netherlands)|June 4, 2014
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancerJoachim von Pawel, Vera Gorbounova, Martin Reck, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survivalSebastian Marwitz, Hans Brunnström, Miklos Gulyas, et al.
Diagnostic Pathology|September 18, 2014
Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLCRania Gaber, Iris Watermann, Christian Kugler, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2023
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectivesMartin Reck, Sanjay Popat, Christian Grohé, et al.
The European Respiratory Journal|March 26, 2026
Clinically Relevant Change in Airway Wall Thickness to Identify Disease Activity in COPD and Smokers At-RiskMustafa Abdo, Martin Reck, Susanne Stiebeler, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2014
Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancerCeline Pallaud, Martin Reck, Erzsebet Juhasz, et al.
JTO Clinical and Research Reports|February 2, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, <i>EGFR</i>-Mutated, Metastatic NSCLC: Outcomes by <i>EGFR</i> Exon 19 Deletion VariantsKazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, et al.
Journal of the National Cancer Institute|August 7, 2003
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancerMartin Reck, Joachim von Pawel, Hans-Nicolas Macha, et al.
Pageof 44

Showing results (131-140 of 437) with videos related to

Sort By:
Pageof 44
Clinical Lung Cancer|May 11, 2023
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122)Nikolaj Frost, Annalen Bleckmann, Frank Griesinger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2011
Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390)Janessa Laskin, Lucio Crinò, Enriqueta Felip, et al.
Lung Cancer (Amsterdam, Netherlands)|June 4, 2014
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancerJoachim von Pawel, Vera Gorbounova, Martin Reck, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survivalSebastian Marwitz, Hans Brunnström, Miklos Gulyas, et al.
Diagnostic Pathology|September 18, 2014
Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLCRania Gaber, Iris Watermann, Christian Kugler, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2023
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectivesMartin Reck, Sanjay Popat, Christian Grohé, et al.
The European Respiratory Journal|March 26, 2026
Clinically Relevant Change in Airway Wall Thickness to Identify Disease Activity in COPD and Smokers At-RiskMustafa Abdo, Martin Reck, Susanne Stiebeler, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2014
Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancerCeline Pallaud, Martin Reck, Erzsebet Juhasz, et al.
JTO Clinical and Research Reports|February 2, 2024
RELAY, Erlotinib Plus Ramucirumab in Untreated, <i>EGFR</i>-Mutated, Metastatic NSCLC: Outcomes by <i>EGFR</i> Exon 19 Deletion VariantsKazumi Nishino, Jin-Yuan Shih, Kazuhiko Nakagawa, et al.
Journal of the National Cancer Institute|August 7, 2003
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancerMartin Reck, Joachim von Pawel, Hans-Nicolas Macha, et al.
Pageof 44